Answer – Notable Changes in Operating Expenses, SG&A, or Other Cost Structures
Based on the excerpt you provided from the Business Wire announcement, the press release only indicates that DiaMedica Therapeutics will release its Q2 2025 financial results and hold a conference call to discuss the business update. The summary does not contain any details about the company’s operating expenses, selling‑general‑and‑administrative (SG&A) costs, or other cost‑structure changes for the quarter.
Therefore, with the information currently available, we cannot identify any specific changes in:
- Operating expenses (e.g., research & development, manufacturing, or other operating cost categories)
- SG&A expenses (e.g., sales, marketing, administrative, or corporate overhead)
- Other cost‑structure items (e.g., cost‑of‑revenue, depreciation, or other non‑operating expenses)
What to do next
- Review the upcoming earnings release (scheduled for after market close on Tuesday, August 12, 2025). The detailed financial statements and management discussion will typically include a breakdown of operating expenses and SG&A, and will highlight any significant changes versus prior periods.
- Listen to the conference call (Wednesday, August 13, 2025 at 8:00 AM ET/7:00 AM CT). Management usually discusses the drivers behind any increases or decreases in expense categories and provides context for any cost‑structure adjustments.
- Check the official press release (often posted on the company’s Investor Relations website) once it is published. It will contain the exact figures and any explanatory commentary on cost changes.
If you obtain the actual earnings release or the transcript of the conference call, you can revisit the question and we’ll be able to provide a detailed analysis of the operating expense, SG&A, and other cost‑structure changes.